Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences:
The sessions will be webcast and can be accessed by visiting the section of the Altimmune website.
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Altimmune Investor & Media Contact:
How Municipalities Like Miami, Denver, and Utah City Are Embracing Blockchain and Cryptocurrency
IoT Evolution Expo #TECHSUPERSHOW Pub Crawl on Expo Floor